Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 101 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,462,974 | -19.7% | 2,103,298 | 0.0% | 0.08% | +18.1% |
| Q2 2023 | $14,281,393 | +43.1% | 2,103,298 | +5.6% | 0.07% | +10.8% |
| Q1 2023 | $9,979,564 | +2.7% | 1,991,929 | 0.0% | 0.06% | -15.6% |
| Q4 2022 | $9,720,614 | -73.4% | 1,991,929 | -21.3% | 0.08% | -67.0% |
| Q3 2022 | $36,505,000 | -18.3% | 2,531,546 | -14.3% | 0.23% | -11.1% |
| Q2 2022 | $44,674,000 | +30.7% | 2,952,671 | +2.6% | 0.26% | +70.1% |
| Q1 2022 | $34,187,000 | +53.1% | 2,877,671 | +108.9% | 0.15% | +83.3% |
| Q4 2021 | $22,332,000 | -32.3% | 1,377,671 | +19.3% | 0.08% | -37.8% |
| Q3 2021 | $32,963,000 | +66.4% | 1,154,961 | +97.1% | 0.14% | +57.0% |
| Q2 2021 | $19,804,000 | +8049.8% | 585,921 | +7197.6% | 0.09% | +4200.0% |
| Q1 2021 | $243,000 | -99.0% | 8,029 | -98.4% | 0.00% | -98.7% |
| Q4 2020 | $25,133,000 | – | 507,633 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |